Industrials - Germany



Buy (old: Buy) 11.11.2024

EUR 7.00 (old: EUR 7.00)

Muted Q3 numbers due to investment reluctance; chg. est.

Topic: MAX released its Q3 numbers last Friday with sales below but EBITDA above our estimates.

Q3 sales came in at € 85m (eNuW: € 90m), a 15% decrease yoy due to a soft order backlog and investment reluctance across all portfolio companies except ELWEMA. EBITDA increased 17% to € 9.3m (eNuW: € 7.1m) due to a € 4.5m profit from a litigation in connection with the sale of NSM Packtec in 2018. However, adjusted by the effect from NSM Packtec, EBITDA would have been 39% lower yoy with a 2.3ppts margin decrease, impacted by economies of scale, wage inflation and product mix effects.

Order intake decreased 13% yoy to € 67m, leading to a low order backlog of € 165m (vs. € 206m in Q3'23). Major contributor to the reduction in order backlog was bdtronic with a sharp decline to € 30m in Q3'24 (vs. € 76m in Q3'23).

Bdtronic's sales decreased 15% yoy to € 22m in Q3 and EBITDA came in at € -0.1m (€ 3.8m in Q3'23) due to a low order intake in H1'24 affected by the EV sales crisis. While bdtronic had to expand its capacities to handle the rapid demand increase during FY23, they are now suffering from a higher cost base and external personnel, which could only slowly be reduced to c. 30 end of Q3'24 from c. 120 at the peak in FY23. Further, the company still has impregnation orders from FY23 in the backlog with lower profitability that will also have a negative impact in Q4'24e. Having said that, bdtronic is still a leading expert in its field and once the cyclical demand recovers, we expect profitability to normalize.

Vecoplan showed a flat sales development in Q3 (\in 46m) but decreased its EBITDA by 40% to \in 3.4m due to a less favorable product mix, a higher headcount and wage inflation. Order intake decreased by 8.9% attributable to postponements from US customers related to the election (North America: 43% of sales). We expect demand to increase in Q4'24e and modest growth for FY25e.

MA micro: MAX Automation received c. € 70m cash inflow for the sale of MA micro of which c. € 60m was used to reduce debt, lifting the equity ratio to a healthy 51% (vs. 30% in Q3'23). This should lead to an interest expense reduction of € 4-5m in FY25e (eNuW). Considering the recent deterioration of MA micro's operating business, we don't expect significant earn-out payments.

Reiterate BUY with an unchanged PT of € 7.00, based on DCF.

Y/E 31.12 (EUR m)	2021	2022	2023	2024e	2025e	2026e
Sales	349.1	342.7	397.4	361.1	378.3	397.4
Sales growth	13.7%	-1.8%	16.0%	-9.1%	4.8%	5.0%
EBITDA	25.7	29.4	34.6	30.1	32.9	35.8
Net debt (if net cash=0)	88.6	95.8	124.5	48.7	30.5	7.4
FCF	20.9	-12.1	6.4	16.2	18.2	23.1
Net Debt/EBITDA	3.4	3.3	3.6	1.6	0.9	0.2
EPS pro forma	-0.05	0.43	0.14	0.13	0.27	0.33
EBITDA margin	7.4%	8.6%	8.7%	8.3%	8.7%	9.0%
ROCE	5.5%	9.6%	8.3%	7.3%	7.7%	9.0%
EV/sales	0.8	0.8	0.8	0.7	0.6	0.5
EV/EBITDA	10.3	9.8	9.6	8.5	7.2	6.0
PER	-130.0	14.4	16.7	46.0	22.8	18.5
Adjusted FCF yield	4.3%	6.7%	5.7%	6.4%	7.1%	8.4%

Source: Company data, NuWays, Close price as of 04.11.2024



Share Performance

	identinei
Bloomberg	MXHN GR
Reuters	MAXG
WKN	A2DA58
ISIN	DE000A2DA588

Idontifior

5,854


Ø trading volume (6 months)


Key snarenoiders						
59.0%						
5.0%						
4.2%						
3.4%						
28.0%						


Estimates changes								
	<u>2024e</u>	<u>2025e</u>	<u>2026e</u>					
Sales	-1%	0%	-0%					
EBIT	3%	-2%	-1%					
EPS	-7%	20%	14%					

Comment on changes

- EBIT estimate increased thanks to the extraordinary € 4.5m settlement payment from the sale of NSM Packtec.
- Interest expenses reduced due to the reduction in net debt.







Company description

MAX Automation is an expert for automation, production and assembly solutions, mostly serving niche applications across various end-markets. The subsidiaries operate in technology and innovative fields including e-mobility, medical, electronics and environmental.

Guidance

- Sales: € 350-380m
- EBITDA: € 27-31m

Update - 11.11.2024



Financials

Profit and loss (EUR m)	2021	2022	2023	2024e	2025e	2026e
Net sales	349.1	342.7	397.4	361.1	378.3	397.4
Sales growth	13.7%	-1.8%	16.0%	-9.1%	4.8%	5.0%
Increase/decrease in finished goods and work-in-process	4.8	21.3	9.2	-0.7	7.7	0.5
Total sales	353.8	364.0	406.6	360.4	386.0	397.9
Other operating income	19.8	9.3	6.7	14.4	9.8	11.9
Material expenses	174.7	186.1	199.5	161.8	185.4	191.9
Personnel expenses	122.5	107.0	122.4	127.8	125.6	131.1
Other operating expenses	50.7	50.9	56.9	55.0	52.0	50.9
Total operating expenses	328.1	334.6	372.0	330.3	353.1	362.0
EBITDA	25.7	29.4	34.6	30.1	32.9	35.8
Depreciation	5.0	4.8	5.8	5.9	5.9	6.0
EBITA	20.7	24.5	28.8	24.2	27.0	29.8
Amortisation of goodwill	0.0	0.0	5.2	0.0	0.0	0.0
Amortisation of intangible assets	9.2	3.1	4.4	5.4	5.0	4.1
Impairment charges	0.0	0.0	0.0	0.0	0.0	0.0
EBIT (inc revaluation net)	11.6	21.5	19.2	18.8	22.0	25.7
Interest income	0.0	0.4	0.1	0.3	0.4	0.4
Interest expenses	8.3	8.8	12.8	12.6	8.0	8.2
Investment income	0.0	2.7	4.6	1.4	1.5	1.6
Financial result	-8.3	-5.7	-8.1	-10.9	-6.1	-6.1
Recurring pretax income from continuing operations	3.2	15.8	11.1	7.9	15.9	19.6
Extraordinary income/loss	0.0	0.0	0.0	0.0	0.0	0.0
Earnings before taxes	3.2	15.8	11.1	7.9	15.9	19.6
Income tax expense	4.1	-0.8	5.5	2.3	4.7	5.8
Net income from continuing operations	-0.9	16.6	5.6	5.5	11.2	13.8
Income from discontinued operations (net of tax)	0.0	1.6	-9.6	0.0	0.0	0.0
Net income	-0.9	15.0	15.2	5.5	11.2	13.8
Minority interest	0.5	0.3	0.0	0.0	0.0	0.0
Net profit (reported)	-1.4	14.7	15.2	5.5	11.2	13.8
Average number of shares	29.5	38.0	41.1	41.1	41.1	41.1
EPS reported	-0.05	0.39	0.37	0.13	0.27	0.33
Profit and loss (common size)	2021	2022	2023	2024e	2025e	2026e
Net sales	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Sales growth	13.7%	-1.8%	16.0%	-9.1%	4.8%	5.0%
Increase/decrease in finished goods and work-in-process	1.4%	6.2%	2.3%	-0.2%	2.0%	0.1%

Profit and loss (common size)	2021	2022	2023	2024e	2025e	2026e
Net sales	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Sales growth	13.7%	-1.8%	16.0%	-9.1%	4.8%	5.0%
Increase/decrease in finished goods and work-in-process	1.4%	6.2%	2.3%	-0.2%	2.0%	0.1%
Total sales	101.4%	106.2%	102.3%	99.8%	102.0%	100.1%
Other operating income	5.7%	2.7%	1.7%	4.0%	2.6%	3.0%
Material expenses	50.0%	54.3%	50.2%	44.8%	49.0%	48.3%
Personnel expenses	35.1%	31.2%	30.8%	35.4%	33.2%	33.0%
Other operating expenses	14.5%	14.9%	14.3%	15.2%	13.7%	12.8%
Total operating expenses	94.0%	97.7%	93.6%	91.5%	93.3%	91.1%
EBITDA	7.4%	8.6%	8.7%	8.3%	8.7%	9.0%
Depreciation	1.4%	1.4%	1.5%	1.6%	1.6%	1.5%
EBITA	5.9%	7.2%	7.2%	6.7%	7.1%	7.5%
Amortisation of goodwill	0.0%	0.0%	1.3%	0.0%	0.0%	0.0%
Amortisation of intangible assets	2.6%	0.9%	1.1%	1.5%	1.3%	1.0%
Impairment charges	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
EBIT (inc revaluation net)	3.3%	6.3%	4.8%	5.2%	5.8%	6.5%
Interest income	0.0%	0.1%	0.0%	0.1%	0.1%	0.1%
Interest expenses	2.4%	2.6%	3.2%	3.5%	2.1%	2.1%
Investment income	0.0%	0.8%	1.2%	0.4%	0.4%	0.4%
Financial result	neg.	neg.	neg.	neg.	neg.	neg.
Recurring pretax income from continuing operations	0.9%	4.6%	2.8%	2.2%	4.2%	4.9%
Extraordinary income/loss	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Earnings before taxes	0.9%	4.6%	2.8%	2.2%	4.2%	4.9%
Tax rate	127.6%	-5.1%	25.0%	30.0%	30.0%	30.0%
Net income from continuing operations	-0.3%	4.8%	1.4%	1.5%	2.9%	3.5%
Income from discontinued operations (net of tax)	0.0%	0.5%	-2.4%	0.0%	0.0%	0.0%
Net income	-0.3%	4.4%	3.8%	1.5%	2.9%	3.5%
Minority interest	0.1%	0.1%	0.0%	0.0%	0.0%	0.0%
Net profit (reported)	-0.4%	4.3%	3.8%	1.5%	2.9%	3.5%
One and One and other North and						

Source: Company data, NuWays

Update - 11.11.2024



Palanas abast (FUD w)	2024	2022	2022	20245	20250	20266
Balance sheet (EUR m) Intangible assets	2021 54.4	2022 54.5	2023 37.8	2024e 34.8	2025e 28.8	2026e 22.4
Property, plant and equipment	43.2	46.1	50.7	53.4	20.0 54.3	55.4
Financial assets	7.1	42.6	47.4	47.4	47.4	47.4
FIXED ASSETS	104.8	143.2	135.9	135.6	130.5	125.2
Inventories	53.5	89.6	92.5	80.9	80.6	83.4
Accounts receivable	31.9	40.1	49.8	42.5	44.5	46.7
Other assets and short-term financial assets	37.2	52.1	41.6	47.0	45.0	46.0
Liquid assets	30.2	35.7	26.6	28.1	45.3	63.4
Deferred taxes	10.6	15.6	16.0	16.5	14.0	14.0
Deferred charges and prepaid expenses	9.6	0.0	0.0	0.0	0.0	0.0
CURRENT ASSETS	173.0	233.1	249.1	215.1	233.7	253.6
TOTAL ASSETS	277.8	376.3	385.0	350.7	364.2	378.8
SHAREHOLDERS EQUITY	39.8	92.9	114.9	181.6	192.8	210.3
MINORITY INTEREST	0.8	0.8	0.0	0.0	0.0	0.0
Long-term liabilities to banks	1.0	117.0	120.9	51.0	50.0	45.0
Bonds (long-term)	0.0	0.0	0.0	0.0	0.0	0.0
other interest-bearing liabilities	31.5	14.0	29.6	25.0	25.0	25.0
Provisions for pensions and similar obligations	0.9	0.6	0.5	0.5	0.5	0.5
Other provisions and accrued liabilities	14.7	14.4	15.2	12.0	13.0	13.0
NON-CURRENT LIABILITIES	48.1	145.9	166.2	88.5	88.5	83.5
Short-term liabilities to banks	86.3	0.5	0.6	0.8	0.8	0.8
Accounts payable	32.2	62.9	52.2	40.7	42.0	44.2
Advance payments received on orders	0.0	0.0	0.0	0.0	0.0	0.0
Accrued taxes	0.7	1.6	3.0	2.0	2.0	2.0
Other liabilities (incl. from lease and rental contracts)	62.1	61.4	38.3	28.0	28.0	28.0
Deferred taxes	7.9	10.3	9.7	9.0	10.0	10.0
Deferred income	0.0	0.0	0.0	0.0	0.0	0.0
CURRENT LIABILITIES	189.1	136.8	103.9	80.5	82.8	85.0
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	277.8	376.3	385.0	350.7	364.2	378.8
Balance sheet (common size)	2021	2022	2023	2024e	2025e	2026e
Intangible assets	19.6%	14.5%	9.8%	9.9%	7.9%	5.9%
Property, plant and equipment	15.6%	12.2%	13.2%	15.2%	14.9%	14.6%
Financial assets FIXED ASSETS	2.6%	11.3%	12.3%	13.5%	13.0%	12.5%
Inventories	37.7% 19.3%	38.1% 23.8%	35.3% 24.0%	38.7% 23.1%	35.8% 22.1%	33.0% 22.0%
Accounts receivable	11.5%	10.6%	12.9%	12.1%	12.2%	12.3%
Other assets and short-term financial assets	13.4%	13.8%	10.8%	13.4%	12.2%	12.3%
Liquid assets	10.9%	9.5%	6.9%	8.0%	12.4%	16.7%
Deferred taxes	3.8%	4.2%	4.2%	4.7%	3.8%	3.7%
Deferred charges and prepaid expenses	3.5%	0.0%	0.0%	0.0%	0.0%	0.0%
CURRENT ASSETS	62.3%	61.9%	64.7%	61.3%	64.2%	67.0%
TOTAL ASSETS	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
SHAREHOLDERS EQUITY	14.3%	24.7%	29.8%	51.8%	52.9%	55.5%
MINORITY INTEREST	0.3%	0.2%	0.0%	0.0%	0.0%	0.0%
Long-term liabilities to banks	0.4%	31.1%	31.4%	14.5%	13.7%	11.9%
Bonds (long-term)	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
other interest-bearing liabilities	11.3%	3.7%	7.7%	7.1%	6.9%	6.6%
Provisions for pensions and similar obligations	0.3%	0.1%	0.1%	0.2%	0.1%	0.1%
Other provisions and accrued liabilities	5.3%	3.8%	3.9%	3.4%	3.6%	3.4%
NON-CURRENT LIABILITIES	17.3%	38.8%	43.2%	25.2%	24.3%	22.1%
Short-term liabilities to banks	31.1%	0.1%	0.2%	0.2%	0.2%	0.2%
	31.170					11.7%
Accounts payable	11.6%	16.7%	13.6%	11.6%	11.5%	11.7%
Accounts payable Advance payments received on orders			13.6% 0.0%	11.6% 0.0%	11.5% 0.0%	0.0%
• •	11.6% 0.0% 0.2%	16.7% 0.0% 0.4%	0.0% 0.8%	0.0% 0.6%	0.0% 0.5%	0.0% 0.5%
Advance payments received on orders	11.6% 0.0% 0.2% 22.3%	16.7% 0.0% 0.4% 16.3%	0.0% 0.8% 10.0%	0.0% 0.6% 8.0%	0.0% 0.5% 7.7%	0.0% 0.5% 7.4%
Advance payments received on orders Accrued taxes Other liabilities (incl. from lease and rental contracts) Deferred taxes	11.6% 0.0% 0.2% 22.3% 2.8%	16.7% 0.0% 0.4% 16.3% 2.7%	0.0% 0.8% 10.0% 2.5%	0.0% 0.6% 8.0% 2.6%	0.0% 0.5% 7.7% 2.7%	0.0% 0.5% 7.4% 2.6%
Advance payments received on orders Accrued taxes Other liabilities (incl. from lease and rental contracts) Deferred taxes Deferred income	11.6% 0.0% 0.2% 22.3% 2.8% 0.0%	16.7% 0.0% 0.4% 16.3% 2.7% 0.0%	0.0% 0.8% 10.0% 2.5% 0.0%	0.0% 0.6% 8.0% 2.6% 0.0%	0.0% 0.5% 7.7% 2.7% 0.0%	0.0% 0.5% 7.4% 2.6% 0.0%
Advance payments received on orders Accrued taxes Other liabilities (incl. from lease and rental contracts) Deferred taxes	11.6% 0.0% 0.2% 22.3% 2.8%	16.7% 0.0% 0.4% 16.3% 2.7%	0.0% 0.8% 10.0% 2.5%	0.0% 0.6% 8.0% 2.6%	0.0% 0.5% 7.7% 2.7%	0.0% 0.5% 7.4% 2.6%

Source: Company data, NuWays

Update - 11.11.2024



Net profitions -9.0 15.0 15.2 5.5 11.2 11.2 11.5	Cook flow statement (FUR m)	2024	2022	2022	20246	20250	20260	
Depreciation of fixed assets (incl. leases)	Cash flow statement (EUR m) Net profit/loss	2021 -0.9	2022 15.0	2023 15.2	2024e 5.5	2025e 11.2	2026e 13.8	
Amortisation of goodwall & inflangible assels 9.2 6.5 10.2 5.4 5.0 4.5 5.0 4.5 5.0 4.5 5.0 4.5 5.0 5.	•						6.0	
Other costs affecting income / expenses	. ,						4.1	
Increase/decrease in invention 10 2 2-9.7 7.3 11.6 0.3 2-9.7 1.5 2.5		21.0	0.3	19.8	4.9	5.9	12.1	
Increase/decrease in accounts receivable 4.8 8.3 -12.8 7.3 2.0 2.0 Increase/decrease in content spayable 8.5 8.4 -22.1 -11.5 0.0 0.0 0.0 Increase/decrease in working capital positions 0.0 0.0 0.0 8.5 0.0 0.0 0.0 Increase/decrease in working capital positions 0.6 -20.6 -33.7 7.4 0.4 -3.6 Cash flow from operating activities 27.7 2.8 17.2 29.2 27.6 3.8 CAPEX 6.8 9.3 10.8 13.0 9.5 9.5 9.7 Payments for acquisitions 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Income from asset disposals 3.6 1.0 1.7 0.0 0.0 0.0 0.0 Income from asset disposals 3.8 1.0 1.7 7.0 0.0 0.0 0.0 Cash flow from investing activities 3.3 4.4 9.1 57.0 9.5 9.4 Cash flow before financing 24.4 -11.2 8.2 86.2 18.2 2.0 2.0 18.2 2.0	Cash flow from operating activities	18.0	-13.5		17.8	16.3	21.1	
Increase/decrease in actourths payable 8.5	Increase/decrease in inventory	-10.2					-2.9	
Increase/decrease in orther working capital positions 6,6 -29,6 -37,5 7.4 2.4 2.5 2.5 2.7 2.8 3.7 7.4 3.7 2.8 3.7 7.4 3.8							-2.2	
Increase/Identified properting activities	. ,						2.1	
Cash flow from oporating activities 27,7 28,8 17,2 29,2 27,6 33 CAPEX 6,8 9,3 11,8 13,9 10,8 13,9 10,8 13,9 10,8 13,0 10,0 0,0<	5						0.0	
CAPEX								
Payments for acquisitions 0.0							9.9	
Financial investments							0.0	
Income from asset disposals 3.6							0.0	
Cash Intow from investing activities 3.3 8.4 9.1 87.0 9.5 9.8 Cash flow before financing 24.4 -11.2 8.2 86.2 18.2 23. Increase/decrease in debt position -37.0 23.8 5.9 7.43 -1.0 -5.0 Capital measures 0.0 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>0.0</td>							0.0	
Increase/decrease in debt position	·	-3.3	-8.4	-9.1	57.0	-9.5	-9.9	
Purchase of own shares 0.0	Cash flow before financing	24.4	-11.2	8.2	86.2	18.2	23.1	
Capital measures	Increase/decrease in debt position	-37.0	23.8	-5.9	-74.3		-5.0	
Dividents paid 0.0							0.0	
Dites							0.0	
Effects of exchange rate changes on cash 0.1 0.5 0.0 0.0 0.0 0.5 Cash flow from financing activities 42.0 16.3 47.3 41.6 41.0 5.5 Increase/decrease in liquid assets -17.5 5.6 -9.1 1.6 17.2 15.5 Koy ratios (EUR m) 2021 2022 2023 2024 2025 2026 PSL growth analysis 35.7 1.18% 16.0% -9.1% 4.8% 5.0° EBITDA growth 13.7% 14.1% 17.7% -12.9% 9.3 8.9° EBIT growth 198.3% 85.7% 10.7% -2.1% 17.3% 16.9° EBY growth -94.7% -914.0% -4.7% -63.8% 101.9% 23.4° EBN growth 1.59.3% 85.7% 10.7% -2.1% 17.3% 16.9° EBY growth -94.7% -914.0% -4.7% -63.8% 101.9% 23.4 EBN growth 1.1 1.1 1.1 2.1 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>0.0</td>							0.0	
Cash flow from financing activities 4-2.0 16.3 -17.3 8-48. -1.0 5. Increase/decrease in liquid assets -17.5 5.6 -9.1 1.8 17.2 18. Liquid assets at end of period 30.2 35.7 26.6 28.1 45.3 63. Koy ratios (EUR m) 2021 2022 2023 2024e 2025e 2026e PRL growth analysis 35.7 1.6.8 16.0% -9.1% 4.8% 5.0° EBIT Day Growth 35.4.7% 11.8% 16.0% -9.1% 4.8% 5.0° EBIT Day growth -150.3 36.7% -10.7% -2.1% 1.93 8.9° EPS growth -94.7% -94.0% -4.7% -63.6% 10.19 23.4° ETRICAPOR 2.1 -94.7% -94.0% -4.7% -63.6% 10.19 23.4° ETRICAPORT 2.1 -94.0% -4.1 -4.1 -4.2 -2.1 -2.1 -2.1 -2.1 -2.1 -2.1							0.0	
Increase/decrease in liquid assets -17.5 5.6 -9.1 1.6 17.2 18. Liquid assets at ond of period 30.2 35.7 26.6 28.1 45.3 63.	<u> </u>							
Main	•						18.1	
Pact Growth analysis 13.7% 1.8% 16.0% 9.1% 4.8% 5.0% 1.8% 1	•						63.4	
Pact prowth analysis							***	
Sales growth 13,7% 1,8% 16,0% -9,1% 4,8% 5,0° EBITDA growth 354,7% 14,1% 17,0% -12,9% 9,3% 8,9% EBIT growth -159,3% 85,7% -10,7% -21,29% 9,3% 8,9% EPS growth -94,7% 914,0% -4,7% -63,6% 101,3% 23,4° ERITDA per employee 16,1 18,4 20,8 17,2 17,9 18. No. employees (average) 1,595 1,595 1,593 1,664 17,2 17,9 18. No. employees (average) 1,595 1,595 1,593 1,664 17,2 17,9 18. No. employees (average) 1,595 1,595 1,593 1,664 10,2 20,2 22,9 21,25 Acy 40x file 1,41,4 1,668 8,0 20,7 22,9 22,9 22,9 22,9 22,9 22,9 22,9 22,9 22,9 22,9 22,9 22,9 22,9		2021	2022	2023	2024e	2025e	2026e	
EBIT DA growth 354,7% 41,1% 17,7% -12,9% 9,3% 8,9 EBIT growth -159,3% 94,7% 914,0% -2,1% 17,3% 18,9 EFS growth -94,7% 914,0% -2,1% 17,3% 10,9 EFICENCY 28 28 206,7 206,2 208 EBIT DA per employee 16,1 1,84 20,8 206,7 206,2 208 EBIT DA per employee 16,1 1,84 20,8 17,2 17,9 18 No. employees (average) 16,1 18,4 20,8 17,2 17,9 18 No. employees (average) 18,1 16,6 18,0% 20,7 20,2 20 3,8 1,9 Balance sheet analysts 18,0 16,6% 18,0% 20,7 2,2% 22,9 21,2 2 2,0 2,3 2 2 2,0 2,3 2 2 2,0 2,3 2 2 2,0 2,1 2 2 <	-	13 7%	_1 8%	16.0%	-0.1%	1 8%	5.0%	
EBIT growth	· ·						8.9%	
PS growth							16.9%	
Efficiency Sales per employee 218.9 215.1 238.8 206.7 206.2 208.2 EBITDA per employee 16.1 18.4 20.8 17.2 17.9 18. No. employees (average) 15.95 1,595 1,593 1,664 17.74 1.835 1,90 Balance sheet analysis Avg. working capital / sales 14.7% 16.6% 18.0% 20.7% 22.9% 21.25 Inventory turnover (sales/inventory) 3.6 2.6 2.2 2.0 2.3 2.2 Accounts receivable turnover 11.8 9.5 8.8 8.5 8.							23.4%	
EBITDA per employee 16.1 18.4 20.8 17.2 17.9 18. No. employees (average) 1,595 1,593 1,664 1,747 1,835 1,90 Balance shet analysis <th color="" of="" par<="" part="" td="" the=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th>	<td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
No. employees (average) Balance sheet analysis Balance sheet analysis Vay. working capital / sales Inventory turnover (sales/inventory) 3.6 2.6 2.2 2.0 2.3 2.2 Accounts receivable turnover 11.8 9.5 8.8 8.5 8.5 8.8 Accounts payable turnover 11.8 9.5 8.8 8.5 8.5 8.8 Accounts payable turnover 11.8 9.5 8.8 8.5 8.5 8.8 Accounts payable turnover 12.5 7.2 6.9 8.9 9.0 9. Cash flow analysis Free cash flow Solvency Net debt 1.5 8.8 8.5 8.5 8.8 1.6 16.2 18.2 23. 1.6 1.6 16.2 18.2 23. 1.6 1.6 16.2 18.2 23. 1.6 1.6 16.2 18.2 23. 1.6 1.6 16.2 18.2 23. 1.6 1.6 16.2 18.2 23. 1.6 1.6 16.2 18.2 23. 1.6 1.6 16.2 18.2 23. 1.6 1.6 16.2 18.2 23. 1.6 1.6 16.2 18.2 23. 1.6 1.6 16.2 18.2 23. 1.6 1.6 16.2 18.2 23. 1.6 1.6 16.2 18.2 23. 1.6 1.6 16.2 18.2 23. 1.6 1.6 16.2 18.2 23. 1.6 1.6 16.2 18.2 23. 1.6 16.2 20.2 20.2 20.2 20.2 20.2 20.2 20.2 2	Sales per employee	218.9	215.1	238.8	206.7	206.2	208.3	
Balance sheet analysis Avg. working capital / sales 14.7% 16.6% 18.0% 20.7% 22.9% 21.2% Inventory tumover (sales/inventory) 3.6 2.6 2.2 2.0 2.3 2.2 Accounts receivable tumover 11.8 9.5 8.8 8.5 8.5 8.5 Accounts payable tumover 12.5 7.2 6.9 8.9 9.0 9.0 Cash flow analysis Free cash flow 20.9 -12.1 6.4 16.2 18.2 23. Free cash flow/sales 6.0% -3.5% 1.6% 4.5% 4.8% 5.8* FCF / net profit 9.0 2.7% 2.7% 29.24% 162.9% 167.7 Capex / sales 2.0% 2.7% 2.7% 3.6% 2.5% 2.5% Solvency 8.8 95.8 124.5 48.7 30.5 7. Net Debt/EBITDA 3.4 3.3 3.6 1.6 0.9 0.0 Net Debt/EBITDA 6.0% 6.3% 9.4% 12.1% 7.1% 11.1							18.8	
Avg. working capital / sales 14.7% 16.6% 18.0% 20.7% 22.9% 21.2% Inventory tumover (sales/inventory) 3.6 2.6 2.2 2.0 2.3 2. Accounts receivable tumover 11.8 9.5 8.8 8.5 8.5 8.5 Accounts payable tumover 12.5 7.2 6.9 8.9 9.0 9.9 Cash flow analysis 20.9 -12.1 6.4 16.2 18.2 2.3 Free cash flow/sales 6.0% -3.5% 1.6% 4.5% 4.8% 5.8% FCF / net profit neg. neg. 42.5% 292.4% 162.9% 167.7% Capex / sales 2.0% 2.7% 2.7% 3.6% 2.5 2.5 Solvency 88.6 95.8 124.5 48.7 30.5 7 Net debt 88.6 95.8 124.5 48.7 30.5 7 Net Debt/EBITDA 3.4 3.3 3.6 1.6 0.9 0.0 Interest paid / avg. debt 6.0% 6.0% 0.0% 0.0% 0.0% 0.0% 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	. , , , , , , , , , , , , , , , , , , ,	1,595	1,593	1,664	1,747	1,835	1,908	
Inventory tumover (sales/inventory) 3.6 2.6 2.2 2.0 2.3 2.0 2.	-	4.4.70/	40.00/	40.00/	00.70/	00.00/	04.00/	
Accounts receivable turnover 11.8 9.5 8.8 8.5 8.5 8.8 Accounts payable turnover 12.5 7.2 6.9 8.9 9.0 9.0 Cash flow analysis Free cash flow 20.9 -12.1 6.4 16.2 18.2 23. Free cash flow/sales 6.0% -3.5% 1.6% 4.5% 4.8% 5.8% FCF / net profit neg. neg. neg. 42.5% 292.4% 162.9% 167.76 Capex / sales 2.0% 2.7% 2.7% 3.6% 2.5% 295.4 162.9% 167.76 Capex / sales 2.0 2.0 2.7% 2.7% 3.6% 2.5% 292.4 162.9% 167.76 Capex / sales 2.0								
Accounts payable tumover 12.5 7.2 6.9 8.9 9.0 9.0 Cash flow analysis Free cash flow was also from a flow of the profit 20.9 -12.1 6.4 16.2 18.2 23.5 Free cash flow/sales 6.0% -3.5% 1.6% 4.5% 4.8% 5.8 FCF / net profit neg. neg. neg. 22.7% 2.7% 3.6% 2.5% 2.5% Solvency Net debt 88.6 95.8 124.5 48.7 30.5 7. Net Debt/EBITDA 3.4 3.3 3.6 1.6 0.9 0.0 Net Debt/EBITDA 3.4 3.3 3.6 1.6 0.9 0.0 Net Debt/EBITDA 3.4 3.3 3.6 1.6 0.9 0.0 Interest paid / avg. debt 6.0% 6.3% 9.4% 12.1% 7.1% 11.1 2.1 2.1 2.1 7.7% 9.0 ROE 5.5% 9.6% 8.3% 7.							2.3 8.5	
Cash flow analysis Free cash flow 20.9 -12.1 6.4 16.2 18.2 23. Free cash flow/sales 6.0% -3.5% 1.6% 4.5% 4.8% 5.8% FCF / net profit neg. neg. 42.5% 292.4% 162.9% 167.7% Capex / sales 2.0% 2.7% 2.7% 3.6% 2.5% 25.5% Solvency Net debt 88.6 95.8 124.5 48.7 30.5 7. Net Debt/EBITDA 3.4 3.3 3.6 1.6 0.9 0.0 Net Debt/EBITDA 6.0% 6.3% 9.4% 12.1% 7.1% 11.1% Returns 8.6 95.8 124.5 48.7 30.5 7. Returns 9.0 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% Returns 9.6 8.3% 7.3% 7.7% 9.0% ROE 5.5% 9.6% 8.3% 7.3% 7.7%							9.0	
Free cash flow 20.9 -12.1 6.4 16.2 18.2 23. Free cash flow/sales 6.0% -3.5% 1.6% 4.5% 4.8% 5.8° FCF / net profit neg. neg. 42.5% 292.4% 162.9% 167.7° Capex / sales 2.0% 2.7% 2.7% 3.6% 2.5% 2.5° Solvency 88.6 95.8 124.5 48.7 30.5 7. Net debt 88.6 95.8 124.5 48.7 30.5 7. Net Debt/EBITDA 3.4 3.3 3.6 1.6 0.9 0.0 Dividend payout ratio 0.0%		12.0	,	0.0	0.0	0.0	0.0	
Free cash flow/sales 6.0% -3.5% 1.6% 4.5% 4.8% 5.8% FCF / net profit neg. neg. 42.5% 292.4% 162.9% 167.7% Capex / sales 2.0% 2.7% 2.7% 3.6% 2.5% 2.55 Solvency 88.6 95.8 124.5 48.7 30.5 7. Net Debt/EBITDA 3.4 3.3 3.6 1.6 0.9 0.0 Dividend payout ratio 0.0%		20.9	-12.1	6.4	16.2	18.2	23.1	
Capex / sales 2.0% 2.7% 2.7% 3.6% 2.5% 2.5% Solvency							5.8%	
Solvency Net debt 88.6 95.8 124.5 48.7 30.5 7.7 Net Debt/EBITDA 3.4 3.3 3.6 1.6 0.9 0.0 Dividend payout ratio 0.0%	FCF / net profit	neg.	neg.	42.5%	292.4%	162.9%	167.7%	
Net debt 88.6 95.8 124.5 48.7 30.5 7. Net Debt/EBITDA 3.4 3.3 3.6 1.6 0.9 0.0 Dividend payout ratio 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% Interest paid / avg. debt 6.0% 6.3% 9.4% 12.1% 7.1% 11.1% Returns 80.6 9.6% 8.3% 7.3% 7.7% 9.0% ROE 5.5% 9.6% 8.3% 7.3% 7.7% 9.0% ROE -3.5% 15.8% 13.2% 3.0% 5.8% 6.5% Adjusted FCF yield 4.3% 6.7% 5.7% 6.4% 7.1% 8.4% Dividend yield 0.0% <td>Capex / sales</td> <td>2.0%</td> <td>2.7%</td> <td>2.7%</td> <td>3.6%</td> <td>2.5%</td> <td>2.5%</td>	Capex / sales	2.0%	2.7%	2.7%	3.6%	2.5%	2.5%	
Net Debt/EBITDA 3.4 3.3 3.6 1.6 0.9 0.0 Dividend payout ratio 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% Interest paid / avg. debt 6.0% 6.3% 9.4% 12.1% 7.1% 11.15 Returns ROCE 5.5% 9.6% 8.3% 7.3% 7.7% 9.0% ROE -3.5% 15.8% 13.2% 3.0% 5.8% 6.5% Adjusted FCF yield 4.3% 6.7% 5.7% 6.4% 7.1% 8.4% Dividend yield 0.0%								
Dividend payout ratio 0.0% 11.1% 7.1% 11.1% 7.1% 11.1% 7.1% 11.1% 7.1% 11.1% 7.1% 9.0% 8.3% 7.3% 7.7% 9.0% 8.0% 8.3% 7.3% 7.7% 9.0% 8.0% 7.3% 7.7% 9.0% 8.0% 6.5% <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td>7.4</td></th<>							7.4	
Interest paid / avg. debt 6.0% 6.3% 9.4% 12.1% 7.1% 11.19 Returns ROCE ROCE 5.5% 9.6% 8.3% 7.3% 7.7% 9.0% ROE -3.5% 15.8% 13.2% 3.0% 5.8% 6.5% Adjusted FCF yield 4.3% 6.7% 5.7% 6.4% 7.1% 8.4% Dividend yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0							0.2	
Returns ROCE 5.5% 9.6% 8.3% 7.3% 7.7% 9.0% ROE -3.5% 15.8% 13.2% 3.0% 5.8% 6.5% Adjusted FCF yield 4.3% 6.7% 5.7% 6.4% 7.1% 8.4% Dividend yield 0.0% <t< td=""><td>. ,</td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	. ,							
ROCE 5.5% 9.6% 8.3% 7.3% 7.7% 9.0% ROE -3.5% 15.8% 13.2% 3.0% 5.8% 6.5% Adjusted FCF yield 4.3% 6.7% 5.7% 6.4% 7.1% 8.4% Dividend yield 0.0%	·	6.0%	6.3%	9.4%	12.1%	7.1%	11.1%	
ROE -3.5% 15.8% 13.2% 3.0% 5.8% 6.5% Adjusted FCF yield 4.3% 6.7% 5.7% 6.4% 7.1% 8.4% Dividend yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0		5 5%	9.6%	8 3%	7 3%	7 7%	a n%	
Adjusted FCF yield 4.3% 6.7% 5.7% 6.4% 7.1% 8.49 Dividend yield 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0							6.5%	
Dividend yield 0.0% 0.0							8.4%	
DPS 0.0 0.3 0.3 0.13 0.27 0.3 0.3 0.3 41.1							0.0%	
EPS reported -0.05 0.39 0.37 0.13 0.27 0.3 Average number of shares 29.5 38.0 41.1 41.1 41.1 41. 41. Valuation ratios P/BV 4.6 2.5 2.2 1.4 1.3 1. EV/sales 0.8 0.8 0.8 0.7 0.6 0. EV/EBITDA 10.3 9.8 9.6 8.5 7.2 6. EV/EBIT 22.9 13.4 17.3 13.6 10.8 8.	•						0.0	
Valuation ratios P/BV 4.6 2.5 2.2 1.4 1.3 1. EV/sales 0.8 0.8 0.8 0.7 0.6 0. EV/EBITDA 10.3 9.8 9.6 8.5 7.2 6. EV/EBIT 22.9 13.4 17.3 13.6 10.8 8.	EPS reported	-0.05	0.39	0.37			0.33	
P/BV 4.6 2.5 2.2 1.4 1.3 1. EV/sales 0.8 0.8 0.8 0.7 0.6 0. EV/EBITDA 10.3 9.8 9.6 8.5 7.2 6. EV/EBIT 22.9 13.4 17.3 13.6 10.8 8.	Average number of shares	29.5	38.0	41.1	41.1	41.1	41.1	
EV/sales 0.8 0.8 0.8 0.7 0.6 0. EV/EBITDA 10.3 9.8 9.6 8.5 7.2 6. EV/EBIT 22.9 13.4 17.3 13.6 10.8 8.								
EV/EBITDA 10.3 9.8 9.6 8.5 7.2 6. EV/EBIT 22.9 13.4 17.3 13.6 10.8 8.							1.2	
EV/EBIT 22.9 13.4 17.3 13.6 10.8 8.							0.5	
							6.0	
ource: Company data, NuWays		22.9	13.4	17.3	13.6	10.8	8.4	
	ource: Company data, NuWays							

Update - 11.11.2024



Disclosures

Disclosures regarding research publications of NuWays AG pursuant to section 85 of the German Securities Trading Act (WpHG)

Indication of conflict of interest

It is essential that any research recommendation is fairly presented and discloses interests of indicates relevant conflicts of interest. Pursuant to section 85 of the German Securities Trading Act (WpHG) a research report has to point out possible conflicts of interest in connection with the analysed company. A conflict of interest is presumed to exist in particular if NuWays AG

- (1) or any other person belonging to the same group with it was part of a consortium within the past twelve months that issued the financial instruments of the analysed company by way of a public offer.
- (2) or any other person belonging to the same group with it has entered into an agreement on the production of the research report with the analysed company.
- (3) or any other person belonging to the same group with it has been party to an agreement on the provision of investment banking services with the analysed company or have received services or a promise of services under the term of such an agreement within the past twelve month.
- (4) The analysed company holds 5% or more of the share capital of NuWays AG.
- (5) holds (a) a net short position or (b) a net long position of 0.5% of the outstanding share capital of the analysed company.
- (6) or any other person belonging to the same group with it is a market maker or liquidity provider in the financial instruments of the issuer.
- (7) or the analyst has any other significant financial interests relating to the analysed company such as, for example, exercising mandates in the interest of the analysed company.
- (8) The research report has been made available to the analysed company prior to its publication. Thereafter, only factual changes have been made to the report.

Conflicts of interest that existed at the time when this research report was published:

Company	Disclosures
MAX Automation SE	2

Historical target price and	rating changes for MAX Auto	mation SE			
Company	Date	Analyst	Rating	Target Price	Close
MAX Automation SE	01.11.2024	Khare, Vaishnavi	Buy	EUR 7.00	EUR 5.56
	01.11.2024	Völk, Konstantin	Buy	EUR 7.00	EUR 5.56
	05.08.2024	Khare, Vaishnavi	Buy	EUR 7.50	EUR 6.08
	05.08.2024	Völk, Konstantin	Buy	EUR 7.50	EUR 6.08
	30.11.2023	Wunderlich, Tim	Buy	EUR 8.20	EUR 5.74
	30.11.2023	Khare, Vaishnavi	Buy	EUR 8.20	EUR 5.74
	09.11.2023	Wunderlich, Tim	Buy	EUR 7.30	EUR 5.90
	09.11.2023	Khare, Vaishnavi	Buy	EUR 7.30	EUR 5.90

Update - 11.11.2024



1. General Information/Liabilities

This research report has been produced for the information purposes of institutional investors only, and is not in any way a personal recommendation, offer or solicitation to buy or sell the financial instruments mentioned herein. The document is confidential and is made available by NuWays AG exclusively to selected recipients in the European Union (EU) or, in individual cases, also in other countries. It is not allowed to pass the research report on to persons other than the intended recipient without the permission of NuWays AG. Reproduction of this document, in whole or in part, is not permitted without prior permission NuWays AG. All rights reserved.

Under no circumstances shall NuWays AG, any of its employees involved in the preparation, have any liability for possible errors or incompleteness of the information included in this research report — neither in relation to indirect or direct nor consequential damages. Liability for damages arising either directly or as a consequence of the use of information, opinions and estimates is also excluded. Past performance of a financial instrument is not necessarily indicative of future performance.

2. Responsibilities

This research report was prepared by the research analyst named on the front page (the "Producer"). The Producer is solely responsible for the views and estimates expressed in this report. The report has been prepared independently. The content of the research report was not influenced by the issuer of the analysed financial instrument at any time. It may be possible that parts of the research report were handed out to the issuer for information purposes prior to the publication without any major amendments being made thereafter.

3. Organisational Requirements

NuWays AG took internal organisational and regulative precautions to avoid or accordingly disclose possible conflicts of interest in connection with the preparation and distribution of the research report. All members of NuWays AG involved in the preparation of the research report are subject to internal compliance regulations. No part of the Producer's compensation is directly or indirectly related to the preparation of this financial analysis. In case a research analyst or a closely related person is confronted with a conflict of interest, the research analyst is restricted from covering this company.

4. Information Concerning the Methods of Valuation/Update

The determination of the fair value per share, i.e. the price target, and the resultant rating is done on the basis of the adjusted free cash flow (adj. FCF) method and on the basis of the discounted cash flow – DCF model. Furthermore, a peer group comparison is made.

The adj. FCF method is based on the assumption that investors purchase assets only at a price (enterprise value) at which the operating cash flow return after taxes on this investment exceeds their opportunity costs in the form of a hurdle rate of 7.5%. The operating cash flow is calculated as EBITDA less maintenance capex and taxes.

Within the framework of the DCF approach, the future free cash flows are calculated initially on the basis of a fictitious capital structure of 100% equity, i.e. interest and repayments on debt capital are not factored in initially. The adjust-

ment towards the actual capital structure is done by discounting the calculated free cash flows with the weighted average cost of capital (WACC), which takes into account both the cost of equity capital and the cost of debt. After discounting, the calculated total enterprise value is reduced by the interest-bearing debt capital in order to arrive at the equity value.

NuWays AG uses the following three-step rating system for the analysed companies:

Buy: Sustainable upside potential of more than 20% within 12 months

Sell: Sustainable downside potential of more than 20% within 12 months.

Hold: Upside/downside potential is limited. No immediate catalyst visible.

The decision on the choice of the financial instruments analysed in this document was solely made by NuWays AG. The opinions and estimates in this research report are subject to change without notice. It is within the discretion of NuWays AG whether and when it publishes an update to this research report, but in general updates are created on a regular basis, after 6 months at the latest. A sensitivity analysis is included and published in company's initial studies.

5. Major Sources of Information

Part of the information required for this research report was made available by the issuer of the financial instrument. Furthermore, this report is based on publicly available sources (such as, for example, Bloomberg, Reuters, VWD-Trader and the relevant daily press) believed to be reliable. NuWays AG has checked the information for plausibility but not for accuracy or completeness.

6. Competent Supervisory Authority

NuWays AG is an affiliated company of Hauck Aufhäuser Lampe Privatbank AG which is under supervision of the BaFin – German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), Graurheindorfer Straße 108, 53117 Bonn and Marie-Curie-Straße 24 – 28, 60439 Frankfurt a.M.

7. Specific Comments for Recipients Outside of Germany

This research report is subject to the law of the Federal Republic of Germany and the European Union (EU). The distribution of this information to other states in particular to the USA, Canada, Australia and Japan may be restricted or prohibited by the laws applicable within this state. If this communication is distributed in the United Kingdom it is solely directed at (i) investment professionals as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FPO") or (ii) high net-worth entities as defined in article 49 of the FPO. This document should not be distributed or forwarded, either directly or indirectly, to any other individuals.

8. Miscellaneous

According to Article 4(1) No. i of the delegated regulation 2016/958 supplementing regulation 596/2014 of the European Parliament, further information regarding investment recommendations of the last 12 months are published under: www.nuways-ag.com

Date of publication creation: 11/11/2024 07:53 AM

Date of publication dissemination: 11/11/2024 07:53 AM

Update - 11.11.2024



Contacts

NuWays AG

Mittelweg 16-17 20148 Hamburg Germany +49 170 119 8648 info@nuways-ag.com www.nuways-ag.com



Christian Sandherr Co-CEO/Analyst

christian.sandherr@nuways-ag.com



Frederik Jarchow Co-CEO/Analyst

frederik.jarchow@nuways-ag.com



Philipp Sennewald

Analyst

philipp.sennewald@nuways-ag.com



Henry Wendisch

Analyst

henry.wendisch@nuways-ag.com



Mark Schüssler

Analyst

mark-hendrik.schuessler@nuways-ag.com



Konstantin Völk

Analyst

konstantin.voelk@nuways-ag.com

Find us on Social Media

Instagram



Twitter/X



<u>Linkedlı</u>

